Tyche Industries Ltd

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross—a technical indicator where the 50-day moving average crosses below the 200-day moving average—suggesting a potential shift towards a bearish trend and signalling long-term weakness in the stock’s price momentum.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 14 August 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked deterioration in its valuation metrics, prompting a downgrade to a Strong Sell rating. The company’s price-to-earnings (P/E) ratio and price-to-book value (P/BV) have shifted significantly, reflecting heightened risk and diminished price attractiveness compared to both historical levels and peer benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended June 2026. The company’s latest results reveal a steep decline in revenue, profitability, and key return metrics, signalling mounting challenges amid a competitive and evolving industry landscape.

Tyche Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Tyche Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Tyche Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 July 2026, providing investors with the latest insights into its performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 29 June 2026. This change reflects a combination of deteriorating financial performance, challenging valuation metrics, and a shift in technical indicators, signalling caution for investors amid ongoing underperformance relative to benchmarks.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 22 June 2026. This change reflects a nuanced assessment of the company’s technical indicators, valuation, financial trends, and overall quality, signalling cautious optimism amid ongoing operational headwinds.

Tyche Industries Ltd is rated Sell by MarketsMOJO, with this rating last updated on 3 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 June 2026, providing investors with the latest insights into its performance and outlook.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 3 June 2026. This change reflects a nuanced improvement in the company’s financial trend and a shift in technical indicators, despite ongoing challenges in valuation and quality metrics.

Tyche Industries Ltd., a micro-cap pharmaceutical manufacturer specialising in glucosamine hydrochloride and bulk drug intermediates, reported a challenging quarter for Q4 FY26 (January-March 2026) with net profit of ₹1.15 crores, marking a decline of 36.81% quarter-on-quarter and 22.34% year-on-year. Despite a strong 53.12% sequential revenue recovery to ₹16.20 crores, the company's operating profitability deteriorated sharply, with operating margins turning negative for the first time in recent quarters. The stock, currently trading at ₹138.00 with a market capitalisation of ₹136.00 crores, has gained 3.41% following the results announcement but faces mounting operational headwinds.

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, reported its quarterly results for March 2026, revealing a nuanced financial performance. While net sales reached a record high of ₹16.20 crores, profitability metrics continued to face headwinds, with operating margins contracting and net profit after tax declining sharply over the past six months.